Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management.
about
Practical issues related to uterine pathology: staging, frozen section, artifacts, and Lynch syndromeMSH6 and PMS2 mutation positive Australian Lynch syndrome families: novel mutations, cancer risk and age of diagnosis of colorectal cancer.The genetic basis of Lynch syndrome and its implications for clinical practice and risk management.Identifying targets of miR-143 using a SILAC-based proteomic approach.Evaluation of Lynch syndrome modifier genes in 748 MMR mutation carriers.Anticipation in lynch syndrome: where we are where we goFrequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer.Genetic testing for Lynch syndrome: family communication and motivationRisk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study.Cancer risk in Lynch Syndrome.Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens.Impact of colonoscopic screening in male and female Lynch syndrome carriers with an MSH2 mutation.Impact of gynecological screening in Lynch syndrome carriers with an MSH2 mutation.Current Lynch syndrome tumor screening practices: a survey of genetic counselors.Postradiation Histiocytic Sarcoma in the Setting of Muir-Torre Syndrome.Genome wide DNA differential methylation regions in colorectal cancer patients in relation to blood related family members, obese and non-obese controls - a preliminary report.Characterization of a novel founderMSH6mutation causing Lynch syndrome in the French Canadian population
P2860
Q28080146-87107663-24CA-41F9-AEEF-6A0E8A122401Q33933576-BA09B975-5E38-4FF6-B6F8-B6CB3D3E32BEQ34081267-5F5620C9-83B9-43D0-9480-114156FF3656Q34120584-253EC719-082C-4F18-A8C1-07075993240DQ35212716-5C3CA49C-2240-4B73-8B78-B87F3641E977Q35560811-1A80E775-078E-4F65-8C81-4A7385638B99Q36385676-EF6DA718-6FAB-4FAB-B3B6-5FB2BD1F5F5AQ36422099-314D9E8E-014E-473B-83F4-CA0DFD9A4D78Q36897112-8B6D1CDB-4D24-4961-B6AB-EC9A978B27C8Q38100658-5BC39AB9-2F05-4080-863F-8C36648FEFD5Q38972979-86F5E2C3-F50A-4BFC-B24C-C75B772BFD51Q43429867-C2E6677B-6A8E-40D2-867B-8250E63EABA6Q44435870-2D3A6F84-ECC0-4C2F-BF7A-87BCCA144C12Q45898127-ADF39AA5-ABF4-4ADA-8A80-C3360AD7C777Q54962567-F7B901ED-EC41-4778-97D0-364259C48FBAQ55360738-581FDD8B-8905-4AF4-9CCB-92ACFB7D7765Q58325135-4D247C67-3839-4A5F-ABBB-9EFD644E6AEC
P2860
Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Cancer risk in MLH1, MSH2 and ...... influence clinical management.
@ast
Cancer risk in MLH1, MSH2 and ...... influence clinical management.
@en
Cancer risk in MLH1, MSH2 and ...... influence clinical management.
@nl
type
label
Cancer risk in MLH1, MSH2 and ...... influence clinical management.
@ast
Cancer risk in MLH1, MSH2 and ...... influence clinical management.
@en
Cancer risk in MLH1, MSH2 and ...... influence clinical management.
@nl
prefLabel
Cancer risk in MLH1, MSH2 and ...... influence clinical management.
@ast
Cancer risk in MLH1, MSH2 and ...... influence clinical management.
@en
Cancer risk in MLH1, MSH2 and ...... influence clinical management.
@nl
P2093
P2860
P356
P1476
Cancer risk in MLH1, MSH2 and ...... influence clinical management.
@en
P2093
Anja Wagner
Carli Mj Tops
Dennis Dooijes
Dewkoemar Ramsoekh
Monique E van Leerdam
P2860
P2888
P356
10.1186/1897-4287-7-17
P577
2009-12-23T00:00:00Z
P5875
P6179
1012353516